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Abstract
Perianal ﬁstulas in Crohn’s disease (CD) represent a highly debilitating and difﬁcult-
to-treat condition. Given emerging supportive evidence, we conducted a systematic
review and meta-analysis of all trials/observational studies to establish the safety and
efﬁcacy of local injections of mesenchymal stem cells (MSCs). The PRISMA-P state-
ment was applied for planning and reporting, and MEDLINE, EMBASE, Web of Sci-
ence, Cochrane, CINAHL, ClinicalTrials.gov database, and ECCO 2017 proceedings
were searched for published observational studies and one-arm and randomized clini-
cal trials (RCTs). Safety was assessed in terms of acute local/systemic events, long-
term events, and relatedness with MSC treatment. Efﬁcacy was evaluated in terms of
external and/or radiological closure of ﬁstula tracks. After a review of 211 citations,
23 studies, including 696 participants, were evaluated. Four were RCTs with a total
of 483 patients. Overall, ﬁstula closure occurred in 80% of MSC-treated patients. In
RCTs, this rate was 64% in the MSC arm and 37% in the control arm (relative risk
(RR) = 1.54). Radiological response occurred in 83% of MSC-treated patients.
Treatment-related adverse events occurred in 1% of MSC-treated patients, with severe
treatment-related adverse events reaching 0% over a median follow-up of 6 months.
In RCTs, treatment-related adverse events occurred in 13% in the MSC arm and 24%
in the control arm (RR = 0.65). The relapse rate was 0. These results suggest that a
local MSC injection is safe and efﬁcacious. Further clinical trials with standardized
end-points are required to ensure the timely implementation of this new therapy in the
management of perianal CD.
Introduction
The development of a ﬁstula track is a relatively common feature
of Crohn’s disease (CD) and is responsible for a large proportion
of its morbidity.1 Perianal ﬁstulas can be particularly challenging
due to severe symptoms such as pain, embarrassing discharge,
and incontinence, with a signiﬁcant reduction of quality of life.2
Today, combined medical and surgical therapy is understood to
perform better than either treatment alone in achieving ﬁstula
healing.3 However, the beneﬁt in terms of sustained ﬁstula clo-
sure has proven to be limited, with a relapse rate of 16% at
1 year, 31% at 3 years, and 40% at 5 years.4,5 In addition, the
need to use biological agents, even in association with conven-
tional immunosuppressants, carries an increased risk of opportu-
nistic infections and other complications.6 Unrelated to CD, a
second and more common etiology of perianal ﬁstulas is crypto-
glandular. These are generally easily managed surgically but
sometimes display the same anatomic complexity and difﬁculty
to treat as those related to CD.7
In the recent past, the use of mesenchymal stem cell
(MSC) injections in the ﬁstula tract has yielded promising
results.8–11 MSCs are multilineage somatic progenitor cells
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endowed with unique biological properties, including the lack of
substantial immunogenicity that allows use across human leuko-
cyte antigen (HLA) barriers12, homing toward sites of active
inﬂammation13 and regenerative capacity.14 Most importantly,
MSCs also exert an extraordinary immunomodulating action on
all cells involved in immune response, with the ultimate effect of
dampening inﬂammation while restoring tolerance.15 Taken
together, these properties make MSCs particularly suitable for
the treatment of conditions characterized by both chronic inﬂam-
mation and tissue damage, such as ﬁstulas in CD. Following a
number of observational studies and case series,8–11 a phase III
double-blind clinical trial was carried out on 212 patients with
nonactive or mildly active CD and complex perianal ﬁstulas
refractory to at least one conventional or biological therapy who
were randomly assigned to receive one local injection of
adipose-derived MSCs (darvadstrocel, formerly Cx601) or a pla-
cebo.16 Those patients who were administered darvadstrocel had
a signiﬁcantly higher rate of combined remission at week 24,16
extending to 52 weeks.17 This has led to a positive opinion from
the Committee for Medicinal Products for Human Use of the
European Medicines Agency regarding using this product to treat
complex perianal ﬁstulas in adults with CD upon an inadequate
response to at least one conventional or biologic therapy. There-
fore, we aimed to carry out a systematic literature review and
meta-analysis of all the data published to evaluate the safety and
efﬁcacy of local injections of MSCs in patients suffering with
CD and cryptoglandular ﬁstulas, with the goal of helping to clar-
ify the correct placement of this novel treatment option in the
therapeutic algorithm.
Materials and methods
Protocol registration. The study protocol was developed
according to the PRISMA-P guidelines18 and was also registered
on the PROSPERO website with the number CRD42017076213,
which can be accessed on https://www.crd.york.ac.
uk/PROSPERO/. A statistical analysis plan was ﬁnalized before
data extraction and analysis.
Information sources and literature search. This sys-
tematic review was conducted and reported in accordance with
the PRISMA guidelines.19 We searched the literature as follows:
(i) using electronic databases MEDLINE/PubMed, EMBASE,
Web of Science, Cochrane databases, CINAHL, and
ClinicalTrials.gov; (ii) hand search of the ECCO 2017 congress
proceedings; and (iii) personal knowledge. The search strategy is
summarized in Tables S1 A,B, Supporting information. Only
original articles and abstracts were selected. Reviews, letters, and
meta-analyses were not considered. All relevant articles pub-
lished through May 15th, 2017 in English, Italian, French, Span-
ish, or German were considered.
Study selection and data collection. An initial study
selection was performed by the librarian based on the eligibility
criteria and the content of the abstract; the selection was super-
vised and reﬁned by the ﬁrst author (RC), and full texts were
downloaded and stored locally. The data were independently
retrieved by two authors (RC and CK), and all discrepancies
were resolved through a joint session by reexamining the papers.
A third author (GRC) was available to reach an agreement if
needed. Data were collected into a database set up in REDCap©
(Research Electronic Data Capture),20 a secure web-based plat-
form, and were subsequently exported into Stata 14 (Stata Corpo-
ration, College Station; TX, USA) for analysis. Information on
study design, study quality, availability of the chosen end-points,
number of patients, and clinical characteristics of the population
was retrieved.
Eligibility inclusion criteria. We included randomized
clinical trials (RCTs) and one-arm clinical trials or cohort studies
on patients with CD or cryptoglandular ﬁstulas, treated with local
injection(s) of autologous or allogeneic MSCs from any source
(alone or versus placebo/comparator or standard of care). Any
dose and follow-up duration was considered.
The following safety end-points were included:
1. Number of patients with adverse events (AEs).
2. Number of patients with treatment-related AEs.
3. Number of patients with severe treatment-related AEs.
4. Number of patients with local acute AEs.
5. Number of patients with local late AEs.
6. Number of patients with systemic acute AEs.
7. Number of patients with systemic late AEs.
8. Number of AEs per patient per month.
9. Number of treatment-related AEs per patient per month.
10. Number of severe treatment-related AEs per patient per
month.
11. Death and hospitalizations.
The following efﬁcacy end-points were retrieved from the
articles (as available):
12. External healing (complete or partial) based on surgical
inspection. In this regard, a ﬁstula track was considered clin-
ically ‘closed’ when it no longer drained despite gentle ﬁn-
ger compression; ﬁstula remission was deﬁned as the
absence of any draining ﬁstula opening, and response was
deﬁned as a reduction of 50% or more in the number of
draining ﬁstulas.
13. Clinical assessment: calculation of clinical indexes of activ-
ity, that is, Crohn’s Disease Activity Index (CDAI21) and
Perianal Disease Activity Index (PDAI22).
14. Deep ﬁstula healing (radiological healing) based on magnetic
resonance imaging (MRI) as evaluated according to the cate-
gories and score proposed by van Assche et al.23 if avail-
able; otherwise, deep healing was considered based on the
description reported in the manuscript.
15. Mucosal healing by endoscopic examination if available.
16. Clinical composite score [combination of (1) and (3)].
17. Fistula recurrence.
Risk of bias. Each individual study was assessed for the risk
of bias. For RCTs, the risk of bias was assessed at the study level
using the Cochrane risk-of-bias assessment instrument.24 Biases
were assessed across four domains: random sequence generation,
allocation concealment, incomplete outcome data, and selective
reporting. The corresponding protocols were examined if pub-
lished. For one-arm clinical trials and cohort studies, we consid-
ered both the incomplete outcome data and methods for
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controlling confounding items. Each item was classiﬁed as having
either a high, low, or unclear risk of bias. A second, subjective,
assessment of bias used a 0–100 (with 100 being the best) visual
analog scale (VAS) and accounted for study design (RCT ranked
highest), complete information provided on efﬁcacy (for instance,
number of patients for each end-point), and complete information
provided on safety (for instance, number of patients/events for
each safety end-point). The reported VAS for each study was the
mean of two authors’/reviewers’ evaluations (RC and CK).
Summary measures and synthesis of results.
Patients’ characteristics were summarized using the median and
25–75th percentiles. Within each study and for each study arm
(as applicable), the cumulative incidence of events was calculated
as the ratio of the total number of patients with events over the
total number of patients overall and in each study arm. The
monthly incidence rate was calculated as the total number of
events over the total number of patients per month in each arm.
The time horizon for acute events (healing and AEs) was set at
2 months, and the median study follow-up was used for late
events. For comparative studies, the relative risk (RR) with its
95% conﬁdence interval (95% CI) for each categorical outcome
and the standardized mean difference (SMD, computed from the
reported mean difference and standard deviation [SD]) for con-
tinuous outcomes were derived from the available data. At least
three studies were required to derive RR and SMD. For compara-
tive studies, study RR and SMD were pooled according to the
DerSimonian and Laird random effects model.25 To this end,
single-arm study cumulative rates and Poisson-based rates over
time estimates were retrieved/calculated. Statistical heterogeneity
among studies was assessed using the Cochran Q test and mea-
sured by the I-squared statistic. The presence of publication bias
was investigated by the possible asymmetry in the funnel plot.
Data were analyzed with Stata 14.
Results
Study selection. As shown in the ﬂowchart in Figure 1, the
bibliographic search identiﬁed 345 articles, leaving 211 (inclusive
of 41 abstracts) after duplicate removal. Twenty full-text articles
and six abstracts were examined for inclusion. After review, an
additional three full-text articles were removed, and a total of
23 studies (17 studies including three substudies and six
abstracts) were retained for the review and meta-analysis.
Study characteristics. As detailed in Table 1, of the
23 publications describing studies,8–11,16,17,26–42 6 were RCTs.
Of these, one17 was a substudy of a previous RCT16 that com-
pared MSC treatment with placebo, and one study,29 where two
dosages of MSCs were randomly used, reported only collapsed
Figure 1 PRISMA ﬂowchart showing study disposition from the bibliographic yield.
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results, leaving four RCTs available for comparison. Of these,
three studies compared MSCs to placebo, while one study com-
pared MSCs to ﬁbrin glue. Ten studies were one-arm clinical tri-
als, and seven were observational (with two substudies). Thirteen
studies (65%) were multicenter.
As for the etiology, all studies included patients with CD
ﬁstulas, except one where patients with cryptoglandular ﬁstulas
were also enrolled31 and one with only the last type included.33
As shown in Table 2, in the vast majority of studies, patients suf-
fering from perianal ﬁstulas were included, and MSCs were
mainly autologous and mostly derived from adipose tissue.
Overall, 696 patients enrolled in the studies were meta-ana-
lyzed: 494 were treated with MSCs, while 202 were in the control
arm. The demographic and clinical characteristics of the enrolled
patients are summarized in Table 3. Half of the patients were male;
the median age across studies was 36 years. The median disease
duration was 10 years. Only a few studies provided information
on CDAI and PDAI scores, smoking habits, comorbidities, or con-
comitant therapy. The dosage of MSC injections ranged from 1 to
9 × 107 cells/mL or 20 to 120 × 106 cells suspended in different
volumes, thus preventing the statistical analysis.
Table 4 details the number of studies that evaluated a
given end-point. As shown, external healing was the efﬁcacy
end-point most frequently evaluated (18 studies and all four com-
parative RCTs), together with ﬁstula recurrence (10 studies and
three of the RCTs). The presence of AEs or severe AEs, includ-
ing mortality, was reported in the majority of the original studies
(17/20), although the relationship with MSC therapy was less fre-
quently assessed. Hospitalization was reported in ﬁve articles.
Results of individual studies and synthesis of
results. The cumulative incidence of safety end-points is
reported in Tables 5 and 6. AEs were observed in 53% of patients
(34% in the observational studies and 61% in the clinical trials,
Table 5). In the four RCTs (Table 6), the cumulative incidence of
AEs was similar between the MSC arm (71%) and the control arm
(66%), with an RR of 1.06 (95% CI: 0.93–1.22). Treatment-related
AEs (e.g. anal abscess and pain) occurred in 13% (95% CI: 5–24)
in the MSC arm compared to 24% (95% CI: 14–35) in the control
arm, with an RR of 0.65 (95% CI: 0.43–0.97) favoring the MSC
arm. Similarly, severe treatment-related AEs, which were rare,
occurred less frequently in the MSC arm (1%, 95% CI: 0–2) than
in the control arm (2%, 95% CI: 0–6). There were no fatal events.
Individual and meta-analysis rates of AEs are shown in
Figures S2–S5, Supporting information.
The cumulative incidences of meeting efﬁcacy end-points
are listed in Tables 7 and 8. External healing (18 studies)
occurred in 80% of patients (84% in the observational studies
and 77% in the clinical trials, Table 7 and Fig. 2a). In the four
RCTs, (Table 8, Fig. 2b) external healing was observed in 64%
Table 1 Studies included in the review and meta-analysis
First author (reference
number)
Year Multicenter Substudy Design Phase/
number
of arms
Arm combination Total number
patients/months
of follow-up
Garcia-Olmo D 26 2010 No Case series —/1 MSC 1/1
Cho YB 27 2013 Yes One-arm clinical trial I/1 MSC 10/2
Lee WY 11 2013 Yes One-arm clinical trial II/1 MSC 43/2
Cho YB 28 2015 Yes Lee WY, 2013 Cohort univariable —/1 MSC 41/24
Choi S†,‡ 29 2013 Yes RCT II/2 Low MSC, high MSC 15/2
Molendijk I 30 2015 Yes RCT II/2 Placebo, MSC 21/3
Panes J 16 2016 Yes RCT III/2 Placebo, MSC 212/6
Garcia-Olmo D 8 2005 No One-arm clinical trial I/1 MSC 5/2
Garcia-Olmo D 32 2003 No Case series —/1 MSC 1/3
Garcia-Olmo D 31 2009 Yes RCT II/2 Placebo, MSC 50/2
Herreros MD§ 33 2012 Yes RCT III/3 MSC, MSC + ﬁbrin glue,
ﬁbrin glue
200/6
Ciccocioppo R 9 2011 No Cohort univariable —/1 MSC 12/12
de la Portilla F 10 2013 Yes One-arm clinical trial II/2 MSC 24/6
Wainstein C 34 2016 No Cohort univariable —/1 MSC 9/4
Garcia -Arranz M 35 2016 Yes One-arm clinical trial II/1 MSC 10/12
Lightnert AL‡ 36 2016 No One-arm clinical trial I/1 MSC 7/6
Moniuszko A‡ 37 2015 No Case series —/1 MSC 1/1
Panes J‡ 17 2018 Yes Panes J, 2016 RCT —/2 Placebo, MSC 131/12
Serrero M‡ 38 2017 Yes One-arm clinical trial II/1 MSC 9/3
Park KJ 39 2015 Yes One-arm clinical trial I/1 MSC 6/6
Ciccocioppo R 40 2015 No Ciccocioppo R, 2011 Cohort univariable —/1 MSC 8/72
Baixauli-Fons J‡ 41 2016 Yes One-arm clinical trial II/1 MSC 15/12
Dietz AB 42 2017 Yes One-arm clinical trial I/1 MSC 12/6
†Two MSC arms; cumulative results reported.
‡Abstract.
§Sixty-eight patients on MSC and 66 patients on ﬁbrin glue arms included in meta-analysis.
MSC, mesenchymal stem cells; RCT, randomized clinical trial.
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of the MSC treated arm and 37% of the control arm, with an RR
of 1.57 (95% CI: 1.07–2.31, Fig. 2c) favoring the MSC arm.
Similarly, in those studies assessing the combined external and
radiological healing end-point, the RR favored the MSC arm; RR
1.57 (95% CI: 1.07–2.31, Table 6). The incidence of radiological
healing (seven studies) was comparable (83% of patients) to that
of external healing (Table 7, Fig. S1a). The meta-analytical inci-
dence rate of ﬁstula recurrence was 0, both in observational
studies (95% CI: 0–1) and in clinical trials (95% CI: 0–4)
(Fig. S1b,c), over a median follow-up of 6 months (25–75th:
2.5–9 months).
Risk of bias. None of the observational studies and single-
arm trials was controlled for confounding, mostly due to the low
number of patients included in each study. Randomization and
concealment was adequate in three RCTs but was unclear or not
Table 2 Study clinical information
First author Year Fistulas Type of ﬁstula Type of MSC MSC source
Garcia-Olmo D 2010 Crohn Rectovaginal Autologous Adipose tissue
Cho YB 2013 Crohn Perianal Autologous Adipose tissue
Lee WY 2013 Crohn Perianal Autologous Adipose tissue
Choi S 2013 Crohn Perianal Autologous Adipose tissue
Molendijk I 2015 Crohn Perianal Allogeneic Bone marrow
Panes J 2016 Crohn Perianal Allogeneic Adipose tissue
Garcia-Olmo D 2005 Crohn Mixed Autologous Adipose tissue
Garcia-Olmo D 2003 Crohn Rectovaginal Autologous Adipose tissue
Garcia-Olmo D 2009 Cryptoglandular and Crohn Mixed Autologous Adipose tissue
Herreros MD 2012 Cryptoglandular Perianal Autologous Adipose tissue
Ciccocioppo R 2011 Crohn Perianal and enterocutaneous Autologous Bone marrow
de la Portilla F 2013 Crohn Perianal Allogeneic Adipose tissue
Wainstein C 2016 Crohn Perianal Autologous Adipose tissue
Garcia -Arranz M 2016 Crohn Rectovaginal Allogeneic Adipose tissue
Lightnert AL 2016 Crohn Perianal Autologous Adipose tissue
Moniuszko 2015 Crohn Rectovaginal Autologous Adipose tissue
Serrero M 2017 Crohn Perianal Autologous Adipose tissue
Park KJ 2015 Crohn Perianal Allogeneic Adipose tissue
Baixauli-Fons J 2016 Crohn Mixed Autologous Adipose tissue
Dietz AB 2017 Crohn Perianal Autologous Adipose tissue
MSC, mesenchymal stem cells.
Table 3 Population characteristics: Distribution over studies (median [25–75th])
Variable Number of studies Overall MSC arm Control arm
Studies 23 (inclusive of three substudies) 23 23 4
Patients 23 696 494 202
Percent male 17 50 (40–60) 46 (22–60) 54.5 (51.5–65.5)
Age (years) 16 36.5 (33–41.5) 35 (32.5–39.5) 41 (37.5–47.5)
CDAI 3 92.7 (89–114) 102.7 (90.2–204) 85 (76–94)
PDAI 3 6.6 (5.2–6.8) 6.8 (4.4–13) 5.9 (5.2–6.6)
Percent with comorbidities 1 75 (75–75) 75 NA
Heart 1 0 0 NA
Hypertension 1 8 8 NA
Diabetes 1 0 0 NA
Lung 1 0 0 NA
Kidney 1 33 33 NA
Liver 1 50 50 NA
Percent currently smoking 1 26.5 (20–33) 20 (20–20) 33
Percent with concomitant therapy 6 88 (58.5–100) 97.5 (77–100) 60.5 (40–81)
Steroid 3 11.5 (5.5–25) 17 (5–33) 6 (6–6)
Immunosuppressants 4 46.5 (28–58) 50 (33.5–66.5) 39. 5 (28–51)
Biological drugs 7 0 (0–61) 0 (0–100) 30.5 (0–61)
Antibiotics 3 39 (12–54) 54 (8–100) 25.5 (12–39)
Disease duration (years) 13 10 (6.5–12) 10 (6.5–12) 8.9 (6.8–11)
CDAI, Crohn’s disease activity index; MSC, mesenchymal stem cells; PDAI, perianal disease activity index.
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described in the other cases. The assessment of missing data was
unclear or not considered in 10 studies, and reporting was lack-
ing in 16 studies. The subjective assessment of the risk of bias
across all studies yielded a median VAS of 22 (25–75th: 11–60).
No evidence of publication bias was elicited from the funnel
plots of the RCTs (Fig. 3) when considering the efﬁcacy end-
points, external healing and the clinical composite, or the safety
end-points, AEs and treatment-related AEs.
Discussion
MSC therapy is an emerging potential treatment for a number of
medical conditions triggered and sustained by a dysregulated
immune response resulting in tissue damage.15 This systematic
literature review with meta-analysis was conducted to assess the
safety and efﬁcacy of MSC local injections in ﬁstulas (most peri-
anal) of both CD and cryptoglandular origin, thus providing
information to clinicians and patients considering this treatment
option. Our analysis clearly shows that the use of MSCs results
in a high rate of external and radiological healing in patients with
perianal CD, up to 80% in observational studies and 64% in
RCTs, with treatment-related AEs seen in approximately 1% of
patients. Remarkably, ﬁstula healing appears durable, with iso-
lated recurrences over a 6-month time period. Among RCTs,
MSC treatment results in an estimated 50% higher rate of ﬁstula
healing compared to the control arm. Conversely, the proportion
of MSC-treated patients with AEs is similar to controls. This evi-
dence supports the concept that MSC local injections represent
an important step forward in ameliorating patient outcomes,
avoiding current invasive surgical procedures, which result in
postoperative complications in a substantial number of cases.43,44
In addition, the surgical technique applied (seton placement,
obturation with ﬁbrin glue or plug, mucosal advancement ﬂap,
muscle transposition, ligation of the inter-sphincteric tract,
sphincteroplasty) differs among centers depending on personal
experience and preference, resulting in disparate outcomes.45 For
medical therapy, the efﬁcacy of biological agents in terms of
complete ﬁstula closure was 64% for inﬂiximab at week 1446
and approximately 30% for adalimumab at week 2647 and for
vedolizumab at week 14,48 while no deﬁnitive data are available
for ustekinumab.49,50 With longer follow-up (around 1 year),
these values fell to 23, 33, and 16%, respectively. For thiopur-
ines, a meta-analysis showed that the efﬁcacy rate after a mean
follow-up of 26 weeks was 54%, with a pooled odds ratio of
4.44 (95% CI: 1.50–13.20) favoring ﬁstula healing.51 Previously,
antibiotics were used as ﬁrst-line therapy but did not result in ﬁs-
tula closure.52
A contributing factor to the difﬁculty in ﬁstula treatment is
the uncertainty of its pathogenesis.1 It is clear that immune mech-
anisms are only one component, and additional factors, such as
the supportive stroma and the microvascular bed, favor the devel-
opment and maintenance of tissue damage. In this regard, MSCs
Table 4 Number of studies with evaluable end-points
Number of studies Overall MSC arm Control arm
Safety
AE (patients) 17 17 4
Related AE (patients) 12 12 3
Severe related AE (patients) 17 17 4
AE (numbers) 14 14 2
Related AE (numbers) 7 7 1
Severe related AE (numbers) 8 8 2
Death acute 20 20 4
Death late 19 19 4
Hospitalization 5 5 /
Efﬁcacy
External healing 18 18 4
Radiological healing 7 7 1
Endoscopic healing 2 2 1
Combined end-point 3 3 3
CDAI 3 3 2
PDAI 3 3 2
Fistula recurrence 10 10 3
AE, adverse events; CDAI, Crohn’s disease activity index; PDAI, peria-
nal disease activity index; MSC, mesenchymal stem cells.
Table 5 Safety end-points: Meta-analytical estimates of cumulative incidence (95% conﬁdence interval) (observational longitudinal studies and
mesenchymal stem cell arm of trials)
Safety end-points Overall Observational studies Clinical trials
N Incidence (95% CI) N Incidence (95% CI) N Incidence (95% CI)
Proportion with AEs 17 0.53 (0.30 0.75) 7 0.34 (0.00 - 0.90) 10 0.61 (0.36–0.83)
Treatment-related 12 0.01 (0.00–0.07) 3 0.00 (0.00–0.00) 9 0.04 (0.00–0.12)
Severe treatment-related 17 0.00 (0.00–0.00) 3 0.00 (0.00–0.00) 14 0.00 (0.00–0.01)
Acute local 8 0.37 (0.00–0.86) 1 0.00 (0.00–0.98) 7 0.41 (0.03–0.88)
Acute systemic 7 0.00 (0.00–0.06) 2 0.50 (0.00–1.00) 5 0.01 (0.00–0.07)
Rate of late local AE/patient/month 7 0.00 (0.00–0.01) 2 0.01 (0.00–0.01) 5 0.00 (0.00–0.03)
Rate of late systemic AE/patient/month 7 0.01 (0.00–0.03) 1 0.00 (0.00–0.01) 6 0.02 (0.00–0.07)
Number of AE/patient/month 13 0.13 (0.05–0.24) 5 0.00 (0.00–0.03) 8 0.26 (0.07–0.52)
Treatment-related 7 0.00 (0.00–0.01) 2 0.00 (0.00–0.02) 5 0.01 (0.00–0.01)
Severe treatment-related 8 0.00 (0.00–0.00) 2 0.00 (0.00–0.00) 6 0.00 (0.00–0.00)
Proportion acute death 20 0.00 (0.00–0.00) 5 0.00 (0.00–0.01) 15 0.00 (0.00–0.00)
Rate of late death per person/month 19 0.00 (0.00–0.00) 4 0.00 (0.00–0.01) 15 0.00 (0.00–0.00)
Rate of rehospitalization per person/months 5 0.01 (0.00–0.03) 2 0.00 (0.00–0.00) 3 0.01 (0.01–0.08)
95% CI, 95% conﬁdence interval; AE, adverse event; N, number of studies.
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are known to exert a multifaceted action not only on those cells
involved in immune response but also on epithelial cells, capil-
laries, and stroma (for review, see Ciccocioppo et al.53). Cur-
rently, the precise mechanism of action of MSCs in ﬁstula
healing is not well understood. In the few studies addressing the
mechanism of action of MSCs in ﬁstula,9,30,35 an increase of T-
cells with regulatory function at both rectal mucosa and periph-
eral blood level was evident.9 However, no modiﬁcation of
Table 6 Safety end-points: Meta-analytical estimates of cumulative incidence (95% conﬁdence interval) and relative risk in randomized clinical
trials
Variable N Incidence MSC arm (95% CI) Incidence CTRL arm (95% CI) RR (95% CI)
Proportion with AEs 4 0.71 (0.35–0.96) 0.66 (0.38–0.8) 1.06 (0.93–1.22)
Treatment-related 3 0.13 (0.05–0.24) 0.24 (0.14–0.35) 0.65 (0.43–0.97)
Severe treatment-related 5† 0.01 (0.00–0.02) 0.02 (0.00–0.06) /
Acute local 2 0.08 (0.03–0.16) 0.05 (0.00–0.13) /
Acute systemic 2 0.00 (0.00–0.03) 0.00 (0.00–0.01) /
Rate of late local AE/patient/month 2 0.00 (0.00–0.00) 0.00 (0.00–0.00) /
Rate of late systemic AE/patient/month 2 0.00 (0.00–0.03) 0.00 (0.00–0.00) /
Number of AE/patient/month 2 0.52 (0.42–0.62) 0.46 (0.34–0.54) /
Treatment-related 1 0.00 (0.00–0.00) 0.00 (0.00–0.19) /
Severe treatment-related 2 0.00 (0.00–0.02) 0.02 (0.00–0.06) /
Rate of rehospitalization per person month 3 0.04 (0.00–0.08) / /
†One substudy.
95% CI, 95% conﬁdence interval; AE, adverse event; CTRL, control; MSC, mesenchymal stem cells; N, number of studies; RR, relative risk.
Table 7 Efﬁcacy end-points: Meta-analytical estimates of cumulative incidence (95% conﬁdence interval) (observational longitudinal studies and
mesenchymal stem cell arm of trials)
Efﬁcacy end-point Overall Observational studies Clinical trials
N Incidence (95% CI) N Incidence (95% CI) N Incidence (95% CI)
Proportion with external healing 18 0.80 (0.70 to 0.89) 5 0.84 (0.58–1.00) 13 0.77 (0.67–0.89)
Partial 14 0.22 (0.10 to 0.36) 4 0.14 (0.00 to 0.43) 10 0.25 (0.12 to 0.40)
Total 16 0.51 (00.40 to 0.62) 5 0.56 (0.28 to 0.83) 11 0.50 (0.38 to 0.62)
Proportion with radiological healing 7 0.83 (0.65 to 0.96) 2 0.72 (0.50 to 0.90) 5 0.88 (0.65 to 1.00)
Proportion with endoscopic healing 2 0.17 (0.04 to 0.35) 1 0.58 (0.28 to 0.85) 1 0.00 (0.00 to 0.22)
Proportion with combined response 3 0.48 (0.40 to 0.57) 0 / 3 0.48 (0.40 to 0.57)
Rate of recurrence (per person months) 10 0.00 (0.00 to 0.01) 4 0.00 (0.00 to 0.03) 6 0.00 (0.00 to 0.04)
Median (25 to –75th) Median (25 to –75th) Median (25 to –75th)
Change in CDAI 3 12 (−5.7 to 195) 1 195 (195 to 195) 2 3.15 (−5.7 to 12.00)
Change in PDAI 3 2.3 (1.8 to 8.5) 1 8.5 (8.5 to 8.5) 2 2.05 (1.80 to 2.30)
95% CI, 95% conﬁdence interval; CDAI, Crohn’s disease activity index; N, number of studies; PDAI, perianal disease activity index.
Table 8 Efﬁcacy end-points: Meta-analytical estimates of cumulative incidence (95% conﬁdence interval) and relative risk (RR) in randomized clini-
cal trials
Variable Number of RCTs Incidence MSC arm (95% CI) Incidence CTRL arm (95% CI) RR (95% CI)
Proportion with external healing 4 0.64 (0.57 to 0.70) 0.37 (0.21 to 0.55) 1.54 (1.03 to 2.29)
Partial 3 0.22 (0.06 to 0.44) 0.09 (0.04 to 0.15) 2.06 (0.60 to 7.04)
Total 3 0.42 (0.24 to 0.62) 0.25 (0.04 to 0.55) 1.34 (1.02 to 1.77)
Proportion with radiological healing 1 0.53 (0.27 to 0.79) 0.27 (0.00 to 0.64) /
Proportion with endoscopic healing 1 0.00 (0.00 to 0.22) 0.00 (0.00 to 0.48) /
Proportion with combined response 3 0.48 (0.40 to 0.57) 0.35 (0.29 to 0.41) 1.57 (1.07 to 2.31)
Rate of recurrence (per person months) 3 0.00 (0.00 to 0.02) 0.00 (0.00 to 0.01) /
Median (25th–75th) Median (25th –75th) SMD
Change in CDAI 2 3.15 (−5.70 to 12.00) −28.10 (−54.00 to −2.20) /
Change in PDAI 2 2.05 (1.80 to 2.30) 0.50 (−0.30 to 1.30) /
95% CI, 95% conﬁdence interval; CDAI, Crohn’s disease activity index; CTRL, control; MSC, mesenchymal stem cells; N, number of studies; PDAI,
perianal disease activity index; RCT, randomized clinical trial; RR, relative risk: SMD, standardized mean difference.
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Figure 2 (a) Cumulative incidence of clinical healing by study design. Diamonds represent the meta-analytical estimate of the cumulative incidence
(95% CI) of clinical healing for observational studies (OBS), for clinical trials (TRIAL), and overall. Dots and whiskers represent the incidences and
95% CIs derived from the single studies. The dotted vertical line corresponds to the overall incidence. (b) Cumulative incidence of clinical healing by
treatment arm in the four randomized clinical trials (RCTs). (c) Relative risk (RR) of healing in the four RCTs. The diamond represents the meta-
analytical estimate of the RR (95% CI) of clinical healing. Dots and whiskers represent the RRs and 95% CIs derived from the single studies. The
continuous vertical line corresponds to null effect, the dotted vertical line to the meta-analytical RR.
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cytokine proﬁle was found at the rectal level30 or in peripheral
blood,35 although neither interleukin-13 nor transforming growth
factor-β, both considered key molecules in ﬁstula pathogenesis,1
were assessed.
Nonetheless, our evidence was obtained from a sizable
number of patients (494 with MSCs and 202 with comparator),
with 412 of them recruited in two RCTs.16,33 We found a strik-
ing effect of MSCs in inducing external healing of the ﬁstula
tracks, with a cumulative rate of 80% in the short term. When
assessing data from observational studies in comparison to
RCTs, the healing rate was similar (84% versus 77%). It is con-
ceivable that the lack of imaging evaluation in several early
studies may have led to an overestimation of beneﬁt; however,
when performed, radiological assessment was generally consis-
tent with the clinical evaluation. Finally, an improvement of the
clinical indexes of activity, CDAI and PDAI, in the studies
where they were assessed is demonstrated, whereas only a few
studies evaluated mucosal healing.9,10 In our opinion, this is an
important end-point as rectal inﬂammation sustains ﬁstula for-
mation.54 Accordingly, we found that mucosal healing paral-
leled ﬁstula closure,9 whereas in the darvadstrocel phase III
trial, the presence of active inﬂammation of the rectal mucosa
was an exclusion criterion.16
A further interesting point is that the results were invariably
favorable despite differences in the anatomy of ﬁstulas (anal, recto-
vaginal, entercutaneous), etiology (CD and/or cryptoglandular),
assessment time point, MSC source, HLA setting, dose, and sched-
ule of injections. This is critical as allogeneic MSCs have the advan-
tage of being widely available without the infrastructure and lag
time needed for the production of autologous clinical-grade
MSCs.55 Overall, a wide heterogeneity in dosage was observed in
the reported articles; thus, the impact of MSC dosage on efﬁcacy
has not yet been established. However, no evidence of a clear dose-
dependent efﬁcacy was observed in the studies where dose escala-
tion was performed.10,11,27,29–31,35,39 Therefore, a deﬁnitive conclu-
sion about optimal dosing cannot be drawn, and standardization of
both cellular concentration and total volume to be injected are
important issues that need to be addressed.55 In this regard, an adap-
tation of both the MSC dosage and number of injections was per-
formed in two studies9,11 in an attempt to address this speciﬁc issue.
Long-standing disease does not seem to hamper MSC efﬁ-
cacy as the mean duration in the studies evaluated was 10 years
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Figure 3 Funnel plots for the identiﬁcation of publication bias for the efﬁcacy end-points in terms of clinical healing (a) and combined healing
(b) and for the safety end-points in terms of adverse events (c) and treatment-related adverse events (d). (LN_IRR, log-transformed incidence rate
ratio; s.e., standard error).
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(range 6.5–12). Whether treating with MSC earlier on in the dis-
ease prevents organ dysfunction and if using serial injections
instead of single administration reduces the recurrence rate are
important issues that remain to be determined. In this regard, we
found an irrelevant rate of ﬁstula recurrence on a median follow-
up of 6 months even though, in all studies, the patients enrolled
had had an inadequate response to conventional or biological
therapy. In contrast, the probability of ﬁstula relapse-free sur-
vival, deﬁned as the percentage of patients who do not need to
restart medical therapy, decreases progressively over time,56
reaching at 88% at 1 year, 50% at 2 years, and 37% at 5 years.40
However, these rates are more favorable than those observed
after biological46–50 or surgical57 therapy.
In contrast with CD ﬁstulas, only scant information is
available on the safety and efﬁcacy of MSC local treatment in
cryptoglandular complex perianal ﬁstulas. Indeed, this condition
was explored in only three studies29,31,33 with contrasting results:
in two studies, the MSC injection proved to be successful in
achieving ﬁstula healing at week 8 [69.2%29 and 71%31], and in
one study, no apparent beneﬁt was shown.33 However, when dis-
secting these last results among the participating centers, the
analysis carried out on the subpopulation treated at the leading
center showed healing rates of 54.55 and 83.33% when using
MSC treatment alone or in combination with ﬁbrin glue, respec-
tively, compared to 18.18% when using ﬁbrin glue alone,33 thus
highlighting the need for standardization techniques and training.
Considering safety, it is widely known that conventional
immunosuppressive and immunomodulant therapies are associ-
ated with severe AEs, including opportunistic infections and the
potential for malignancy.58 In contrast, the safety proﬁle of
MSCs appears favorable. The most frequently reported
treatment-related AEs were anal abscess and proctalgia that
developed in 17.5 and 29.4% of the MSC and placebo arm,
respectively, in the pivotal phase III trial and were attributed to
the surgical procedure.16 Moreover, although 53 of 107 MSC-
treated patients developed anti-HLA class I antibodies, there was
no association with positivity for donor-speciﬁc antibodies and
AEs or therapeutic response.16 The most important issue when
evaluating the long-term safety of cellular therapies is malig-
nancy. In this regard, a potential carcinogenic risk had been pos-
tulated based on the in vitro demonstration of MSC malignant
transformation.59,60 However, this ﬁnding was subsequently
refuted by the same authors and explained by cross-culture con-
tamination.61,62 When moving to in vivo results, our data con-
ﬁrmed previous evidence of absence of cancer development
among patients who underwent intravascular MSC treatment,63
and neither ectopic growth of tissues nor opportunistic infections
have been recorded. Possibly, the absence of long-term engraft-
ment might protect against this risk, while the anti-inﬂammatory
effect might contribute to reducing the risk of tumor develop-
ment. Indeed, patients with perianal ﬁstulas in CD have an
increased risk of malignancy,64–66 with the inﬂammatory milieu
being the main driving force.67 Finally, neither fertility nor preg-
nancy has been shown to be affected by MSC local therapy.68
In conclusion, despite the lack of standardization in the col-
lection of end-points and information derived mostly from uncon-
trolled observational studies and one-arm clinical trials, the
possibility of achieving sustained ﬁstula closure with favorable
safety makes MSCs an attractive therapeutic strategy for patients
with perianal ﬁstulas in CD. Therefore, local MSC therapy should
appropriately be placed in the treatment algorithm of this condition.
Further studies aimed at assessing dosage and schedule of MSC
injections, functional potency of the cellular suspension, donor het-
erogeneity, implementation of the manufacturing process, and efﬁ-
cacy of this treatment in comparison with biologics using
standardized safety and efﬁcacy end-points are required. Finally,
although the cost-effectiveness was beyond the scope of this work,
this represents a crucial point that needs to be appropriately
investigated.
Acknowledgments
The authors are grateful to the librarian Ms Chiara Rebufﬁ for
her contribution to the bibliographic search and screening. This
study was funded by Takeda Pharmaceutical Company Limited.
References
1 Panés J, Rimola J. Perianal ﬁstulizing Crohn’s disease: pathogenesis,
diagnosis and therapy. Nat. Rev. Gastroenterol. Hepatol. 2017; 14:
652–64.
2 Mahadev S, Young JM, Selby W, Solomon MJ. Quality of life in
perianal Crohn’s disease: what do patients consider important? Dis.
Colon Rectum. 2011; 54: 579–85.
3 Yassin NA, Askari A, Warusavitarne J et al. Systematic review: the
combined surgical and medical treatment of ﬁstulising perianal
Crohn’s disease. Aliment. Pharmacol. Ther. 2014; 40: 741–9.
4 Bouguen G, Siproudhis L, Gizard E et al. Long-term outcome of peri-
anal ﬁstulising Crohn’s disease treated with inﬂiximab. Clin. Gastro-
enterol. Hepatol. 2013; 11: 975–81.
5 Molendijk I, Nuij VJ, van der Meulen-de Jong AE. Disappointing
durable remission rates in complex Crohn’s disease ﬁstula. Inﬂamm.
Bowel Dis. 2014; 20: 2022–8.
6 Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor
necrosis factor-α therapy in inﬂammatory bowel disease: meta-
analysis of randomized controlled trials. Am. J. Gastroenterol. 2013;
108: 1268–76.
7 Whiteford MH, Kilkenny J III, Hyman N et al. Practice parameters
for the treatment of perianal abscess and ﬁstula-in-ano (revised). Dis.
Colon Rectum. 2005; 48: 1337–42.
8 Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C,
Rodriguez-Montes JA. A phase I clinical trial of the treatment of
Crohn’s ﬁstula by adipose mesenchymal stem cell transplantation.
Dis. Colon Rectum. 2005; 48: 1416–23.
9 Ciccocioppo R, Bernardo ME, Sgarella A et al. Autologous bone
marrow-derived mesenchymal stromal cells in the treatment of ﬁstu-
lising Crohn’s disease. Gut. 2011; 60: 788–98.
10 de la Portilla F, Alba F, García-Olmo D, Herrerías JM, González FX,
Galindo A. Expanded allogeneic adipose-derived stem cells (eASCs)
for the treatment of complex perianal ﬁstula in Crohn’s disease:
results from a multicenter phase I/IIa clinical trial. Int. J. Colorectal
Dis. 2013; 28: 313–23.
11 Lee WY, Park KJ, Cho YB et al. Autologous adipose tissue-derived
stem cells treatment demonstrated favorable and sustainable therapeu-
tic effect for Crohn’s ﬁstula. Stem Cells. 2013; 31: 2575–81.
12 Sundin M, Ringdén O, Sundberg B, Nava S, Gotherstrom C, Le Blanc
K. No alloantibodies against mesenchymal stromal cells, but presence
of anti-fetal calf serum antibodies, after transplantation in allogeneic
hematopoietic stem cell recipients. Haematologica. 2007; 92: 1208–15.
13 Sordi V. Mesenchymal stem cell homing capacity. Transplantation.
2009; 87: S42–5.
Mesenchymal stem cells in perianal ﬁstulas R Ciccocioppo et al.
258 JGH Open: An open access journal of gastroenterology and hepatology 3 (2019) 249–260
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and
John Wiley & Sons Australia, Ltd.
14 Jiang Y, Jahagirdar BN, Reinhardt RL et al. Pluripotency of mesenchy-
mal stem cells derived from adult marrow. Nature. 2002; 418: 41–9.
15 Ben-Ami E, Berrih-Aknin S, Miller A. Mesenchymal stem cells as an
immunomodulatory therapeutic strategy for autoimmune diseases.
Autoimmun. Rev. 2011; 10: 410–5.
16 Panés J, García-Olmo D, Van Assche G et al. Expanded allogeneic
adipose-derived mesenchymal stem cells (Cx601) for complex peria-
nal ﬁstulas in Crohn’s disease: a phase 3 randomised, double-blind
controlled trial. Lancet. 2016; 388: 1281–90.
17 Panés J, García-Olmo D, Van Assche G et al. ADMIRE CD Study
Group Collaborators. Long-term efﬁcacy and safety of stem cell ther-
apy (Cx601) for complex perianal ﬁstulas in patients with Crohn’s
disease. Gastroenterology. 2018; 154: 1334–42.
18 Moher D, Shamseer L, Clarke M et al. Preferred reporting items for
systematic review and meta-analysis protocols (PRISMA-P) 2015 state-
ment. Syst. Rev. 2015; 4: 1. https://doi.org/10.1186/2046-4053-4-1.
19 Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Pre-
ferred reporting items for systematic reviews and meta-analyses: the
PRISMA statement. Ann. Intern. Med. 2009; 151: 264–9.
20 Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG.
Research electronic data capture (REDCap)—a metadata-driven meth-
odology and workﬂow process for providing translational research
informatics support. J. Biomed. Inform. 2009; 42: 377–81.
21 Best WR, Beckel JM, Singleton JW, Kern F. Development of a
Crohn’s disease activity index: National Cooperative Crohn’s disease
Study. Gastroenterology. 1976; 70: 439–44.
22 Gecse KB, Bemelman W, Kamm MA et al. A global consensus on
the classiﬁcation, diagnosis and multidisciplinary treatment of peria-
nal ﬁstulising Crohn’s disease. Gut. 2014; 63: 1381–92.
23 van Assche G, Vanbeckevoort D, Bielen D et al. Magnetic resonance
imaging of the effects of inﬂiximab on perianal ﬁstulizing Crohn’s
disease. Am. J. Gastroenterol. 2003; 98: 332–9.
24 Higgins JPT, Green S, eds. Cochrane Handbook for Systematic
Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration,
2011. Available from URL: http://handbook.cochrane.org
25 DerSimonian R, Laird N. Meta-analysis in clinical trials. Control.
Clin. Trials. 1986; 7: 177–88.
26 García-Olmo D, Herreros D, De-La-Quintana P et al. Adipose-
derived stem cells in Crohn’s rectovaginal ﬁstula. Case Rep. Med.
2010; 2010: 1–3. https://doi.org/10.1155/2010/961758.
27 Cho YB, Lee WY, Park KJ, Kim M, Yoo HW, Yu CS. Autologous
adipose tissue-derived stem cells for the treatment of Crohn’s ﬁstula:
a phase I clinical study. Cell Transplant. 2013; 22: 279–85.
28 Cho YB, Park KJ, Yoon SN et al. Long-term results of adipose-
derived stem cell therapy for the treatment of Crohn’s ﬁstula. Stem
Cells Transl. Med. 2015; 4: 532–7.
29 Choi S, Park K, Kim D et al. Autologous adipose tissue-derived mes-
enchymal stem cells for the treatment of complex perianal ﬁstulas.
Dis. Colon Rectum. 2013; 56: 4.
30 Molendijk I, Bonsing BA, Roelofs H et al. Allogeneic bone marrow-
derived mesenchymal stromal cells promote healing of refractory
perianal ﬁstulas in patients with Crohn’s disease. Gastroenterology.
2015; 149: 918–27.
31 García-Olmo D, Herreros D, Pascual I et al. Expanded adipose-
derived stem cells for the treatment of complex perianal ﬁstula: a
phase II clinical trial. Dis. Colon Rectum. 2009; 52: 79–86.
32 Garcia-Olmo D, Garcia-Arranz M, Gomez Garcia L et al. Autologous stem
cell transplantation for treatment of rectovaginal ﬁstula in perianal Crohn’s
disease: a new cell-based therapy. Int. J. Colorectal Dis. 2003; 18: 451–4.
33 Herreros MD, Garcia Arranz M, Guadalajara H et al. Autologous
expanded adipose-derived stem cells for the treatment of complex
cryptoglandular perianal ﬁstulas: a phase II randomized clinical trial
(FATT 1: Fistula Advanced Therapy Trial 1) and long-term evalua-
tion. Dis. Colon Rectum. 2012; 55: 762–72.
34 Wainstein C, Quera R, Kromberg U et al. Mesenchymal stem cells
and platelet-rich plasma in the treatment of patients with perianal
Crohn’s disease. Int. J. Colorectal Dis. 2016; 31: 725–6.
35 Garcia-Arranz M, Herreros MD, Gonzalez-Gomez C et al. Treatment
of Crohn’s-related rectovaginal ﬁstula with allogeneic expanded-
adipose derived stem cells: a phase I-IIa clinical trial. Stem Cells
Translational Med. 2016; 5: 1441–6.
36 Lightnert AL, Dozois E, Fletcher JG, Dietz A, Friton J, Faubion W.
Early results using an adipose derived mesenchymal stem cells coated
ﬁstula plug for the treatment of refractory perianal ﬁstulizing Crohns
Disease. Gastroenterology. 2016; 150: S483.
37 Moniuszko A, Sarnowska A, Rogowski W, Durlik M, Rydzewska G.
Adipose derived regenerative cells injection as a novel method of entero-
vesical ﬁstula treatment in Crohn’s disease: a case report. J. Crohns Coli-
tis. 2015; 9: S282.
38 Serrero M, Philandrianos C, Visee C et al. An innovative treatment
for refractory perianal ﬁstulas in Crohn’s disease: local micro reinjec-
tion of autologous fat and adipose derived stromal vascular fraction.
J Crohns Colitis. 2017; 11: OP008.
39 Park KJ, Ryoo S-B, Kim JS et al. Allogeneic adipose-derived stem
cells for the treatment of perianal ﬁstula in Crohn’s disease: a pilot
clinical trial. Colorectal Dis. 2015; 18: 468–76.
40 Ciccocioppo R, Gallia A, Sgarella A, Kruzliak P, Gobbi PG,
Corazza GR. Long-term follow-up of Crohn disease ﬁstulas after
local injections of bone marrow-derived mesenchymal stem cells.
Mayo Clin. Proc. 2015; 90: 747–55.
41 Baixauli-Fons J, Nunez-Cordoba JM, Garcia-Olmo D et al. Cell ther-
apy in patients with ﬁstulous Crohn’s disease is safe and effective: a
phase I-II clinical trial. Colorectal Dis. 2016; 18: 24.
42 Dietz AB, Dozois EJ, Fletcher JG et al. Autologous mesenchymal stem
cells, applied in bioabsorbable matrix, for treatment of perianal ﬁstulas
in patients with Crohn’s disease. Gastroenterology. 2017; 153: 59–62.
43 van Koperen PJ, Saﬁruddin F, Bemelman WA, Slors JFM. Outcome
of surgical treatment for ﬁstula in ano in Crohn’s disease. Br. J. Surg.
2009; 96: 675–9.
44 Ritchie RD, Sackier JM, Hodde JP. Incontinence rates after cutting
seton treatment for anal ﬁstula. Colorectal Dis. 2009; 11: 564–71.
45 Akiba RT, Rodrigues FG, da Silva G. Management of complex peri-
neal ﬁstula disease. Clin. Colon Rectal Surg. 2016; 29: 92–100.
46 Sands BE, Anderson FH, Bernstein CN et al. Inﬂiximab maintenance ther-
apy for ﬁstulizing Crohn’s disease. N. Engl. J. Med. 2004; 350: 876–85.
47 Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for main-
tenance of clinical response and remission in patients with Crohn’s
disease: the CHARM trial. Gastroenterology. 2007; 132: 52–65.
48 Feagan BG, Schwartz D, Danese S et al. Efﬁcacy of Vedolizumab in
ﬁstulising Crohn’s disease: exploratory analyses of data from GEM-
INI 2. J. Crohns Colitis. 2018; 12: 621–6.
49 Sands BE, Gasink C, Jacobestein D et al. Fistula healing in pivotal
studies of ustekinumab in Crohn’s disease. Presented at DDW 2017.
Gastroenterology. 2017; 152: S185.
50 Battat R, Bessissow T, Strohl M et al. Ustekinumab for the treatment
of perianal ﬁstulas in patients with Crohn’s disease. J. Crohns Colitis.
2017; 11: S400–1.
51 Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and
6-mercaptopurine in Crohn disease. A meta-analysis. Ann. Int. Med.
1995; 123: 132–42.
52 Present DH. Crohn’s ﬁstula: current concepts in management. Gastro-
enterology. 2003; 124: 1629–35.
53 Ciccocioppo R, Cangemi GC, Kruzliak P, Corazza GR. Cellular ther-
apies: the potential to regenerate and restore tolerance in immune-
mediated intestinal diseases. Stem Cells. 2016; 34: 1474–86.
54 Schwartz DA, Ghazi LJ, Regueiro M et al. Guidelines for the multi-
disciplinary management of Crohn’s perianal ﬁstulas: summary state-
ment. Inﬂamm. Bowel Dis. 2015; 21: 723–30.
R Ciccocioppo et al. Mesenchymal stem cells in perianal ﬁstulas
JGH Open: An open access journal of gastroenterology and hepatology 3 (2019) 249–260
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and
John Wiley & Sons Australia, Ltd.
259
55 Ciccocioppo R, Corazza G. Mesenchymal stem cells for ﬁstulising
Crohn’s disease. Lancet. 2016; 388: 1251–2.
56 Guadalajara H, Herreros D, De-La-Quintana P, Trebol J, Garcia-
Arranz M, Garcia-Olmo D. Long-term follow-up of patients
undergoing adipose-derived adult stem cell administration to treat
complex perianal ﬁstulas. Int. J. Colorectal Dis. 2012; 27:
595–600.
57 van der Hagen SJ, Baeten CG, Soeters PB, van Gemert WG. Long-
term outcome following mucosal advancement ﬂap for high perianal
ﬁstulas and ﬁstulotomy for low perianal ﬁstulas: recurrent perianal ﬁs-
tulas: failure of treatment or recurrent patient disease? Int.
J. Colorectal Dis. 2006; 21: 784–90.
58 Levy C, Tremaine WJ. Management of internal ﬁstulas in Crohn’s
disease. Inﬂamm. Bowel Dis. 2002; 8: 106–11.
59 Rubio D, Garcia-Castro J, Martin MC et al. Spontaneous human adult
stem cell transformation. Cancer Res. 2005; 65: 3035–9.
60 Rosland GV, Svendsen A, Torsvik A et al. Long-term cultures
of bone marrow-derived human mesenchymal stem cells fre-
quently undergo spontaneous malignant transformation. Cancer
Res. 2009; 69: 5331–9.
61 Torsvik A, Røsland GV, Svendsen A et al. Spontaneous malignant
transformation of human mesenchymal stem cells reﬂects cross-con-
tamination: putting the research ﬁeld on track—letter. Cancer Res.
2010; 70: 6393–6.
62 Garcia S, Bernad A, Martin MC, Cigudosa JC, Garcia-Castro J, de
la Fuente R. Pitfalls in spontaneous in vitro transformation of
human mesenchymal stem cells. Exp. Cell Res. 2010; 316:
1648–50.
63 Lalu MM, McIntyre L, Pugliese C et al. Safety of cell therapy with
mesenchymal stromal cells (SafeCell): a systematic review and meta-
analysis of clinical trials. PLoS One. 2012; 7: e47559.
64 Iesalnieks I, Gaertner WB, Glass H et al. Fistula-associated anal ade-
nocarcinoma in Crohn’s disease. Inﬂamm. Bowel Dis. 2010; 16:
1643–8.
65 Baars JE, Kuipers EJ, Djkstra G et al. Malignant transformation of
perianal and enterocutaneous ﬁstulas is rare: results of 17 years of
follow-up from The Netherlands. Scand. J. Gastroenterol. 2011; 46:
319–25.
66 Papaconstantineou I, Mantzos DS, Kondi-Paﬁti A, Koutroubakis IE.
Anal adenocarcinoma complicating chronic Crohn’s disease. Int.
J. Surg. Case Rep. 2015; 10: 201–3.
67 Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inﬂam-
mation. Nature. 2008; 454: 436–44.
68 Sanz-Baro R, Garcia-Arranz M, Guadalajara H, de la Quintana P,
Herreros MD, Garcia-Olmo D. First-in-human case study: preg-
nancy in women with Crohn’s perianal ﬁstula treated with adipose-
derived stem cells: a safety study. Stem Cells Transl. Med. 2015; 4:
598–602.
Supporting information
Additional supporting information may be found in the online
version of this article at the publisher’s website:
Figure S1 (a) Cumulative incidence of radiological healing by
study design, (b) of ﬁstula recurrence by study design, and (c) of
ﬁstula recurrence by treatment arm in the four randomized clini-
cal trials. Diamonds represent the meta-analytical estimate of the
cumulative incidence (95% conﬁdence interval [95% CI]). Dots
and whiskers represent the incidences and 95% CI derived from
the single studies. The dotted vertical line corresponds to the
overall incidence.
Figure S2 (a) Cumulative incidence of adverse events by study
design, (b) of treatment related adverse events by study design,
and (c) of severe treatment related adverse events by study
design.
Figure S3 (a) Cumulative incidence of local acute adverse events
by study design, (b) of systemic acute adverse events by study
design, (c) incidence of local late adverse events by study design,
and (d) of systemic late adverse events by study design.
Figure S4 (a) Incidence of hospitalization by study design;
(b) acute mortality by study design; and (c) late mortality by
study design.
Figures S5 (a) Incidence of adverse events by treatment arm in
randomized clinical trials, (b) of treatment-related adverse events
by treatment arm in randomized clinical trials, and (c) of severe
treatment-related adverse events by treatment arm in randomized
clinical trials.
Table S1A Search strategy 1 (performed on 2017-05-13).
Table S1B Search strategy 2 (performed on 2017-05-13).
Mesenchymal stem cells in perianal ﬁstulas R Ciccocioppo et al.
260 JGH Open: An open access journal of gastroenterology and hepatology 3 (2019) 249–260
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and
John Wiley & Sons Australia, Ltd.
